US5728152A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bioresorbable heart valve support
Assignee: St Jude Medical LLC
•
Filing: 1995-06-07
•
Granted: 1998-03-17
•
Expires: 2015-06-07
Abstract
Abstract This invention relates to bioprosthetic heart valve stents that are fashioned of bioresorbable materials. Such stents may be configured as sheaths or frames contoured to the shape of a valvular graft. The stents are eventually resorbed by the patient, leaving a functional "stentless" valve with improved hemodynamic characteristics compared to stented valve implants.
Inventors
- 👤 II M. William Mirsch
- 👤 Katherine S. Tweden
- 👤 Todd D. Campbell
- 👤 Bruce D. Ward
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:06
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/24; A61F2/2409; A61F2/2412; A61L; A61L27/00; A61L27/50; A61L27/507; A61L31/00; A61L31/14; A61L31/148; A61F2/2418; A61F2210/00; A61F2210/0004; A61F2250/00; A61F2250/0014; A61F2250/003; A61F2250/0031; Y; Y10; Y10S; Y10S623/00; Y10S623/90
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
51 words
A bioprosthetic heart valve comprising a valvular tissue graft secured to a biocompatible, is contoured to said valvular tissue graft, said bioprosthetic heart valve being appropriate for joining with valve-receiving cardiac tissue, wherein said stent is operably resorbed following substantially complete healing of said heart valve with said valve-receiving cardiac tissue.
Claim 2
Dependent Claim
51 words
A bioprosthetic heart valve comprising a valvular tissue graft secured to a biocompatible, is contoured to said valvular tissue graft, said bioprosthetic heart valve being appropriate for joining with valve-receiving cardiac tissue, wherein said stent is operably resorbed following substantially complete healing of said heart valve with said valve-receiving cardiac tissue.
Claim 3
Dependent Claim
21 words
The bioprosthetic heart valve of claim 1, wherein said valvular tissue graft is adapted to function at an aortic valve position.
Claim 4
Dependent Claim
21 words
The bioprosthetic heart valve of claim 1, wherein said valvular tissue graft is adapted to perform at a mitral valve position.
Claim 5
Dependent Claim
21 words
The bioprosthetic heart valve of claim 1, wherein said valvular tissue graft is adapted to perform at a tricuspid valve position.
Claim 6
Dependent Claim
21 words
The bioprosthetic heart valve of claim 1, wherein said valvular tissue graft is adapted to perform at a pulmonic valve position.
Claim 7
Dependent Claim
15 words
The bioprosthetic heart valve of claim 1, wherein said sheath comprises a biocompatible, resorbable polymer.
Claim 8
Dependent Claim
37 words
The bioprosthetic heart valve of claim 6, wherein said polymer is selected from the group consisting of dextran, hydroxyethyl starch, gelatin, derivatives of gelatin, polyvinylpyrolidone, polyvinyl alcohol, poly N-(2-hydroxypropyl)methacrylamide!, polyglycols, polyesters, poly (orthoesters), poly (ester-amides) and polyanhydrides.
Claim 9
Dependent Claim
34 words
The bioprosthetic heart valve of claim 7, wherein said polyesters are selected from the group consisting of poly (hydroxy acids) and copolymers thereof, poly ( epsilon!-caprolactone), poly (dimethyl glycolic acid) and poly (hydroxy butyrate).
Claim 10
Dependent Claim
33 words
The bioprosthetic heart valve of claim 6, wherein said polymer is selected from the group consisting of D,L-polylactic acid, L-polylactic acid, glycolic acid and copolymers of D,L-polylactic acid, L-polylactic acid, and glycolic acid.
Claim 11
Dependent Claim
14 words
The bioprosthetic heart valve of claim 6, wherein said sheath is of non-uniform rigidity.
Claim 12
Dependent Claim
19 words
The bioprosthetic heart valve of claim 6, wherein said polymer is invested with one or more biological response modifiers.
Claim 13
Dependent Claim
30 words
The bioprosthetic heart valve of claim 11, wherein said one or more biological response modifiers are selected from the group consisting of cell adhesion molecules, growth factors and differentiation factors.
References Cited (Backward Citations)
US4816029A
Cited
US4680031A
Cited
US4753652A
Cited
US5133755A
Cited
GB2206395A
Cited
US5306286A
Cited
US5080670A
Cited
US5412068A
Cited
US5085629A
Cited
US5258021A
Cited
US5376112A
Cited
US5489297A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-03-16 | 2001-09-15 | 2002-03-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-03-16 | 2005-09-15 | 2006-03-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-03-16 | 2009-09-15 | 2010-03-17 | $7700.00 | Window Closed / Lapsed |